|
Data collection measures | Baseline | 12 weeks | 52 weeks |
|
Demographics (e.g., age, gender, education, and ethnic background) | √ | | |
Past medical history including diabetes complications, comorbidities, and presence of cardiometabolic risk factors | √ | | |
Weight, blood pressure, blood glucose level, and body mass index (BMI) | √ | √ | √ |
Medications (includes names, dose, and frequency of all medications currently prescribed) | √ | √ | √ |
Blood test (HbA1c, kidney and liver function, urine albumin-to-creatinine ratio, serum lipids, and full blood count) | √ | √ | √ |
Serum-based liver fibrosis scores (Fibrosis-4 (FIB-4) Index for Liver Fibrosis [30], AST to Platelet Ratio Index (APRI) [31], and Nonalcoholic Fatty Liver Disease (NAFLD) fibrosis score [32]) | √ | √ | √ |
International Physical Activity Questionnaire (IPAQ) short form [33] | √ | √ | √ |
Readiness to change lifestyle behaviour using validated questionnaire based on the transtheoretical (“stages of change”) questionnaire which includes readiness to change diet (7 items), physical activity (5 items), and weight (1 item) [34, 35] | √ | √ | √ |
Quality of life using EuroQol Five-Dimension (EQ-5D) Health State Utility and Visual Analog Scale (VAS) [36, 37] | √ | √ | √ |
Wellbeing using World Health Organization Five (WHO-5) Well-Being Index [38] | √ | √ | √ |
Feasibility and fidelity of the service | √ | | √ |
|